About Intercept Pharmaceuticals (adapted from Intercept Pharmaceuticals prospectus): Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing their expertise in bile acid chemistry. Intercept's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions.
This description is adapted from Intercept Pharmaceuticals prospectus. This description is not intended to be a recommendation to buy stock from this company. We do not claim that all of the statements above were researched and found to be true. We present them as a general description based on what the company has said about itself at the time that they submitted their prospectus for an IPO offering. To see the company's full description, view their prospectus..
IPO Boutique aggregates information on public companies and private companies, such as Intercept Pharmaceuticals IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Our research is available by annual or monthly subscription or by one-week snapshots and single-company reports. Be informed.
Get our comprehensive reports. Monthly or Annual subscriptions—